PATENT CLAIM ANALYSIS

Application Number: 16241839
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "253040"]

Abstract:
Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1 , X 2 , X 3  and X 4  have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Claim (Index 2):
The method of  claim 1 , wherein the compound is ((S)-4-(6-(4-(2-hydroxy-3-phenylpropanoyl)piperazin-1-yl)pyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 99.0
- Lexical Diversity: 1.63462
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15860852', '15860808', '15858240', '15860894', '15861244']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.805519847460299
- 35 USC 102 Novelty (BERT): 0.5908852646429417
- Combined Prediction Score: 0.7840563891785634
- Mean Citation Score: 467.299754
- Max Citation Score: 481.11722
- Similarity Product: 459.2933849498379

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test